Eliem Therapeutics Total Liabilities 2021-2024 | CLYM
Eliem Therapeutics total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Eliem Therapeutics Annual Total Liabilities
(Millions of US $) |
| 2023 |
$3 |
| 2022 |
$6 |
| 2021 |
$6 |
| 2020 |
$50 |
Eliem Therapeutics Quarterly Total Liabilities
(Millions of US $) |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$3 |
| 2023-12-31 |
$3 |
| 2023-09-30 |
$3 |
| 2023-06-30 |
$4 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
$6 |
| 2022-09-30 |
$6 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$7 |
| 2021-12-31 |
$6 |
| 2021-09-30 |
$6 |
| 2021-06-30 |
$158 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
|
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
